Highest-materiality recent filing
Shuttle Pharma completes merger with United Dogecoin, pivots to crypto, raises $9.55M PIPE
Merger with United Dogecoin closed May 6; Shuttle issued 8,403 Series B-1 Preferred shares convertible at $1.24.
Shuttle Pharmaceuticals to acquire United Dogecoin, becomes public Dogecoin miner with $11M PIPE
Merger consideration: 8,000 Series B-1 preferred shares convertible into ~32.3M common shares at $1.24 per share.
Shuttle Pharma prelim FY2025 net loss widens to ~$11-12M; G&A up 3.6x on investor ads
Preliminary FY2025 net loss expected between $10.9M and $12.1M vs $9.1M in FY2024; revenue remains zero.
Shuttle Pharma issues 19.99% stake (320,496 shares) in accelerated asset purchase payment
First Amendment to Asset Purchase Agreement dated Dec 23, 2025 accelerates partial payment in stock.
Shuttle Pharma acquires AI drug discovery assets for up to $10M; $3M cash paid at close
Acquired substantially all assets of 1542770 BC Ltd. for total consideration up to $10M: $3M cash at close, $3M in 6 months, $2M in 1 year, plus up to $2M contingent milestone payments.
Shuttle Pharma discontinues Ropidoxuridine trial, settles $557K debt for $300K
Settlement with Theradex: $300K payment in full for ~$557K debt; both parties release claims.
Stockholders' equity was $1,394,161 on Sept 30, 2025, below Nasdaq's $2.5M minimum.
Shuttle Pharmaceuticals raises $2.5M via private placement of pre-funded warrants
Pre-funded warrant for 625,156 shares at $0.001 exercise price, immediately exercisable.
Shuttle Pharma signs $10M term sheet to buy Molecule assets; CRO Theradex terminates, seeks $1.09M
Binding term sheet for $10M purchase of substantially all assets and liabilities of Molecule; consideration in cash and stock per Shuttle's sole discretion, with milestones.
Shuttle Pharma pays $1.45M to IR Agency for 2-month marketing services
Consulting agreement with IR Agency LLC signed Sept 15, 2025; fee $1,450,000 for a 2-month term.
President, COO and Secretary Peter Dritschilo resigns effective July 24, 2025
Peter Dritschilo resigned as President, Chief Operating Officer and Secretary on July 24, 2025.
Shuttle Pharma raises $4.25M in private placement of common stock and pre-funded warrants
Gross proceeds of $4.25M from sale of 21,924 shares and 1,158,953 pre-funded warrants at $3.60 per unit.
Effective May 21, 2025, all salaried employees and named executive officers face a 70% salary reduction.
CSO and VP Regulatory resign; shareholders authorize reverse split and large issuances
Dr. Anatoly Dritschilo resigned as CSO and director effective May 9, 2025; no disagreement cited.
Filed provisional patent for PSMA-targeted PARP inhibitor conjugates, co-invented by Dr. Alan Kozikowski who contributed to Pylarify and Pluvicto.
Shuttle Pharma pays $2M to IR Agency for 3-month marketing services
Entered consulting agreement with IR Agency LLC to provide marketing and advertising services to the financial community.
Shuttle Pharma appoints Christopher Cooper interim CEO; founder Dritschilio CSO & Chairman
Christopher Cooper appointed interim CEO effective March 30, 2025.
Shuttle Pharma raises $5.75M in public offering, regains Nasdaq equity compliance
Closed underwritten offering of 1.34M shares and 17.8M pre-funded warrants at $0.30/share, net proceeds ~$5.2M.
Shuttle Pharma appoints Christopher Cooper as interim Co-CEO to boost business activities
Christopher Cooper appointed interim Co-CEO effective March 11, 2025; focused on capital markets and business capabilities.
Revolving loan up to $2M from Bowery Consulting Group; 18% annual interest, 1-year maturity.
Shuttle pays $75K to permanently waive Alto's right to $10M additional notes, warrants
Paid $75,000 to Alto Opportunity Master Fund for permanent waiver of right to purchase up to $10M in additional notes and warrants.
Shuttle Pharma reaches 25% enrollment in Phase 2 trial of Ropidoxuridine for glioblastoma
Initial randomization targets 40 patients: 20 at 1,200 mg/day, 20 at 960 mg/day to identify optimal dose.
Shuttle Pharma receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025
Received Nasdaq letter Dec 31, 2024 for failing to maintain minimum $1.00 bid price for 30 consecutive business days.
Shuttle Pharma doses first three patients in Phase 2 glioblastoma trial; raises $4.5M
First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma; screening for additional patients ongoing.
Shuttle Pharma closes $4.5M public offering of stock and warrants for clinical trials
Gross proceeds of ~$4.5M from 395,574 shares, 2.55M pre-funded warrants, 2.95M common warrants at $1.525/unit.
Shuttle Pharma doses first three patients in Phase 2 trial of Ropidoxuridine for glioblastoma
First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma.
Shuttle Pharma completes enrollment agreements for Phase 2 Ropidoxuridine glioblastoma trial
All six trial sites finalized: Georgetown, UNC, UVA, Hackensack, Allegheny Health Network, Miami Cancer Institute.
Shuttle Pharma closes $600K convertible note offering; CEO invests $237.5K
Closed $600,000 of an up to $1.3 million senior secured convertible note and warrant offering.
Shuttle Pharma receives Nasdaq delisting notice for low equity ($801K vs $2.5M)
Nasdaq notified Shuttle Pharma on Sept 10, 2024 of non-compliance with minimum stockholders' equity of $2.5M; reported equity $801,434.
Shuttle Pharma begins Phase 2 glioblastoma trial; regains Nasdaq compliance
Phase 2 trial of Ropidoxuridine for glioblastoma opened at two sites; four more anticipated this month.
Shuttle Pharma receives Nasdaq non-compliance notice for late Q2 10-Q filing
Nasdaq notified on Aug 21, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delayed Q2 10-Q.
the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time.
On May 3, 2026 (the “ Termination Date ”), independent director Oleh Nabyt resigned from the Board of Directors of Shuttle, effective as of the Termination Date.
On May 9, 2025, Michael P. Vander Hoek submitted his resignation from the position of Vice President, Regulatory, of the Company, effective June 10, 2025.
On May 9, 2025, Dr. Anatoly Dritschilo, resigned as Chief Scientific Offer and director of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately.
Effective March 30, 2025, the Company’s Board of Directors approved the appointment of Christopher Cooper to the position of interim Chief Executive Officer
Anatoly Dritschilo, M.D., to the position of Chief Scientific Officer. Dr. Dritschilo will also continue to hold the position of Chairman of the Board of Directors.
On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).
the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company
the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company
each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company
the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company
each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company
Max materiality 0.95 · Median 0.62 · Most common event other_material